Case Series: COVID-19 in African American Patients With Sarcoidosis

Michael Manansala, Christian Ascoli, Ana Goico Alburquerque, David Perkins, Mehdi Mirsaedi, Patricia Finn, Nadera J. Sweiss

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Data on the clinical presentation and outcomes of sarcoidosis patients with coronavirus disease 19 (COVID-19) are scarce. In this case series, we identified 5 out of 238 sarcoidosis patients who are enrolled in an ongoing longitudinal observational study who developed COVID-19 during the study period and follow their clinical course. Four patients recovered completely, whereas one patient expired during hospital admission. Our preliminary experience suggests that African American patients with chronic sarcoidosis treated with disease-modifying anti-rheumatic drugs (DMARDs) or anti-tumor necrosis factor (TNF) therapy do not seem to be at increased risk of respiratory or life-threatening complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared with the general population, although at the present time, we advocate for maintaining a high level of vigilance and strict follow-up in this patient population.

Original languageEnglish (US)
Article number588527
JournalFrontiers in Medicine
StatePublished - Nov 4 2020


  • African American (AA)
  • COVID- 19
  • DMARDs
  • SAR-CoV-2
  • immunosuppression
  • sarcoidosis

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Case Series: COVID-19 in African American Patients With Sarcoidosis'. Together they form a unique fingerprint.

Cite this